Current Report Filing (8-k)
October 14 2022 - 3:02PM
Edgar (US Regulatory)
0001357459
false
0001357459
2022-10-14
2022-10-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 14, 2022 (October 11, 2022)
PALISADE
BIO, INC.
(Exact
name of Registrant as Specified in Its Charter)
Delaware |
|
001-33672 |
|
52-2007292 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
7750
El Camino Real
Suite
5200
Carlsbad,
California |
|
92009
(Zip
Code)
|
(Address
of Principal Executive Offices) |
|
|
Registrant’s
telephone number, including area code: (858) 704-4900
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.01 per share |
|
PALI |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 |
Entry into a Material Definitive Agreement |
The
information set forth in item 5.02 of this Current Report on Form 8-K is incorporated by reference herein in its entirety.
Item
5.02. |
Departure
of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
Departure
of Principal Executive Officer
Effective
October 11, 2022 (the “Effective Date”), Thomas Hallam, Ph.D., the Chief Executive Officer and a member of the Board of Directors
(the “Board”) of Palisade Bio, Inc. and its wholly owned subsidiary, Leading Biosciences, Inc. (collectively the “Company”)
resigned as both Chief Executive Officer and as a member of the Board, of both entities, to pursue other opportunities. Dr. Hallam’s
resignation from the Board was not as a result of any matter relating to the Company’s operations, policies or practices. In
connection with Dr. Hallam’s resignation, Dr. Hallam and the Company entered into a separation agreement and release (“Hallam
Separation Agreement”). Pursuant to the Hallam Separation Agreement, and in lieu of any compensation owed under the terms of his
employment agreement, Dr. Hallam and the Company mutually released each other from any and all causes of action, rights or claims in
any way connected to his employment with the Company in exchange for (i) the payment of an aggregate of $530,000 payable in twelve (12)
equal monthly installments, (ii) a maximum of twelve (12) months of continued COBRA coverage, (iii) twelve (12) months of immediate vesting
of all outstanding options awards previously granted to him which are subject to time based vesting, and (iv) up to six (6) months of
virtual job-placement services at a value of $3,100. The Hallam Separation Agreement also contains customary provisions for an
employment-based release. The foregoing summary of the Hallam Separation Agreement is qualified in its entirety by the terms of the Hallam
Separation Agreement attached to this Current Report on Form 8-K as Exhibit 10.01.
Appointment
of Interim Principal Executive Officer
As
of the Effective Date, J.D. Finley, the Company’s current Chief Financial Officer, was appointed by the Board to serve as the Company’s
Chief Executive Officer (principal executive officer), on an interim basis. Mr. Finley will additionally continue to serve as the Company’s
Chief Financial Officer and principal accounting officer.
J.D.
Finley, age 65, has served as the Company’s Chief Financial Officer since April 2021. Previously, Mr. Finley served as Leading
Biosciences, Inc’s (the Company’s wholly owned subsidiary and predecessor company) Chief Financial Officer since January
2017 and as a member of board of directors of Leading Biosciences, Inc. (the “LBS Board”) since December 2014. Prior to joining
Leading Biosciences, Inc., Mr. Finley was Chief Executive Officer of PointAcross, Inc., a marketing company, from January 2016 to January
2017. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses,
and was CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. From March 2011 to June
2012 Mr. Finley was Executive Vice President, and from June 2012 to April 2014, Mr. Finley was President of Goldmail. Mr. Finley received
a B.A. in business administration from Boise State University and an M.S. in Taxation from the University of Denver.
There
is no arrangement or understanding between Mr. Finley and any other person pursuant to which Mr. Finley was selected as the Company’s
interim Chief Executive Officer. Except as described herein, there are no existing or currently proposed transactions to which the Company
or any of its subsidiaries is a party and in which Mr. Finley has a direct or indirect material interest. There are no family relationships
between Mr. Finley and any of the directors or officers of the Company.
On
October 11, 2022, the Company issued a press release announcing the appointment of Mr. Finley as interim Chief Executive Officer. A copy
of the press release is attached to this Current Report on Form 8-K as Exhibit 99.01.
Item
9.01 | Financial
Statement and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.
Date:
October 14, 2022 |
Palisade
Bio, Inc. |
|
|
|
|
/s/
J.D. Finley |
|
By: |
J.D.
Finley |
|
|
Interim
Chief Executive Officer and Chief Financial Officer |
Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Seneca Biopharma Inc (NASDAQ): 0 recent articles
More Palisade Bio, Inc. News Articles